SOURCE: OxySure Systems, Inc.

OxySure Systems, Inc.

August 19, 2015 08:30 ET

OxySure (OXYS) Reports Second Quarter 2015 Results With Stellar Growth and Solid Balance Sheet Improvements

Revenues up 62%; Assets up 110%

FRISCO, TX--(Marketwired - August 19, 2015) - OxySure Systems, Inc. (OTCQB: OXYS) ("OxySure," or the "Company"), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its "oxygen from powder" technology and other medical solutions, today announced financial and operating results for the second quarter ended June 30, 2015.

Second Quarter 2015 Highlights:

  • Total revenue up 54% to $1,046,019 for the three months ended June 30, 2015
  • Total revenue up 62% to $1,670,533 for the six months ended June 30, 2015
  • Gross profit up 54% to $636,836 for the three months ended June 30, 2015
  • Gross profit up 64% to $925,494 for the six months ended June 30, 2015
  • Total cash up 344% to $2,875,941 at June 30, 2015 from $647,093 at December 31, 2014
  • Working capital surplus up 441% to $2,264,512 at June 30, 2015 from $418,734 at December 31, 2014
  • Total assets up 110% to $5,282,567 at June 30, 2015 from $2,511,448 at December 31, 2014
  • Stockholder equity up 179% to $2,997,385 at June 30, 2015 from $1,074,788 at December 31, 2014.

Julian T. Ross, Chairman of the Board and Chief Executive Officer of OxySure stated, "We are pleased with our results for the second quarter, and our momentum continues to build. With revenues up 62%, total assets up 110% and stockholder equity up 179% for the year, we believe we are well positioned to achieve our goals for the remainder of the year. These include growing our sales force, solidifying our medical device platform, and uplisting our Company to a national exchange."

For the three months ended June 30, 2015, revenues increased 54% to $1,046,019 as compared to $678,111 for the prior period. Total revenue increased 62% to $1,670,533 for the six months ended June 30, 2015 as compared to $1,034,340 for the prior period.

Gross profit increased 54% to $636,836 for the three months ended June 30, 2015 as compared to $413,255 for the prior period. Gross profit increased 64% to $925,494 for the six months ended June 30, 2015 as compared to $563,894 for the prior period.

On a consecutive quarter basis, the Company's financial results were even more impressive. Revenue was up 67% from 1Q15 to 2Q15, and gross profit was up 120%. The Company's net loss per share went down from $.05 per share for the three months ended March 31, 2015 to $.04 per share for the three months ended June 30, 2015.

Selling, general and administrative expenses for the three months ended June 30, 2015 were $1,247,915 compared to $689,248 for the three months ended June 30, 2014. Sales and marketing expenses increased to $329,393 during the three months ended June 30, 2015, up from $154,044 during the three months ended June 30, 2014, as the Company expanded its sales and marketing, branding and investor relations efforts.

Other general and administrative expenses increased to $621,066 for the three months ended June 30, 2015 as compared to $259,230 during the prior period, primarily as a result of the previously announced increases in staffing in the sales department, as well as increases is stock based compensation expense and professional fees.

Interest expense increased to $561,791 for the three months ended June 30, 2015, as compared to $85,980 for the prior period, primarily as a result of an increase in the amortization of debt discounts and beneficial conversion features (BCF) and warrant fair values. In addition, the Company recorded $204,272 in derivative expense for the quarter, as compared to zero in the prior period.

Net loss during the three months ended June 30, 2015 was $1,258,434, or $0.04 per share, as compared to $319,508 or $0.01 per share during the three months ended June 30, 2014. The weighted average shares outstanding were 30,215,788 and 25,996,642 for three months ended June 30, 2015 and 2014, respectively.

Exceptional Balance Sheet Improvements

The Company reported exceptional improvements to its balance as follows:

  • Total cash equivalents increased 344% to $2,875,941 at June 30, 2015 from $647,093 at December 31, 2014;
  • Working capital surplus increased 441% to $2,264,512 at June 30, 2015 from $418,734 at December 31, 2014;
  • Total assets increased 110% to $5,282,567 at June 30, 2015 from $2,511,448 at December 31, 2014; and
  • Stockholder equity increased 179% to $2,997,385 at June 30, 2015 from $1,074,788 at December 31, 2014.

Business updates

OxySure continues to gather momentum and build its business as a medical device platform company and an emerging leader in the emergency medical and resuscitation space. During the past quarter, the Company:

  • Signed a distribution agreement with Z-Medica, LLC, a leading developer of bleeding control and hemostatic devices like the QuikClot Combat Gauze®;
  • Was selected as an official Supplier of Medical Equipment for Health Services at Special Olympics World Games Los Angeles 2015 (LA2015); the OxySure Model 615 emergency oxygen device was deployed into all the competition venues and medical operations of the Games, along with Automated External Defibrillators (AEDs) and OxySure branded pulse oximeters supplied by the Company. During the Games the OxySure Model 615 was used in 18 lives saved;
  • Appointed three new Territory Managers in Minneapolis, Philadelphia, and San Antonio. These appointments followed other appointments during 1Q2015 of Territory Managers in Michigan, Georgia, Colorado, Western Pennsylvania, Arizona, and North Texas;
  • Signed a distribution agreement with Team Life of New Jersey, an established organization in emergency health training and products with three locations in Middlesex, Cherry Hill and Colts Neck, New Jersey; and
  • Unveiled plans for a medical drone solution to be utilized in aerial operations in support of emergency response and services, disaster response and recovery, search and rescue, and humanitarian relief efforts.

The Company continues to focus on growth by expanding its direct sales force and its global distribution channel, and by diversifying its product portfolio. The Company also plans to continue to ramp up its sales and marketing activities to drive sales, raise market awareness and grow its brand. The Company has also made significant progress towards its goal of uplisting the Company to a national stock exchange.

"We are excited about the direction we are headed, and we look forward to pursuing our goals for remainder of 2015," said Mr. Ross. "There is a lot of work ahead of us, and we plan to execute."

Earnings Conference Call

OxySure's CEO Julian Ross will host a conference call to discuss the Company's second quarter 2015 results. To join the Audio Conference, please dial the phone number at least ten minutes prior to the start of the conference call and enter your passcode as follows:

Date: Wednesday, August 19, 2015

Time: 9:00 pm ET

US Dial-In: 1 (866) 352-2112 Audience US Toll Free

International Dial-In: 1 (630) 691-2779 Audience US Toll

Passcode: 7500 647

A PowerPoint presentation to be used during the call will be made available under "Investor Events" at the following link prior to the call:

For webcast link/ http://www.oxysure.com/aed/index.php/investors-home

PowerPoint slide

Deck

Please dial in at least 10-minutes before the call to ensure timely participation.

About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. www.OxySure.com

Forward-Looking Statements

Statements in this earnings release that are not historical facts are considered to be forward-looking statements. Such statements include, but are not limited to, statements regarding management beliefs and expectations, based upon information available at the time the statements are made, regarding future plans, objectives and performance. All forward-looking statements are subject to risks and uncertainties, many of which are beyond management's control and actual results and performance may differ significantly from those contained in forward-looking statements. OxySure Systems, Inc. intends any forward-looking statement to be covered by the Litigation Reform Act of 1995 and is including this statement for purposes of said safe harbor provisions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. OxySure Systems, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date as of which such statements are made. A discussion of certain risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements is included in OxySure Systems, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2014.

 
OXYSURE SYSTEMS INC. 
  
CONDENSED BALANCE SHEETS 
  
   June 30,   December 31,  
   2015   2014  
   (Unaudited)      
          
ASSETS         
       
Current assets         
       
Cash and cash equivalents  $2,875,941   $647,093  
         
Accounts receivable, net   711,148    369,575  
         
Inventories   422,551    277,346  
         
License fee receivable   448,308    463,308  
         
Prepaid expenses and other current assets   91,747    53,588  
         
Total current assets   4,549,695    1,810,910  
            
Property and equipment, net   88,617    91,537  
         
Intangible assets, net   347,650    362,764  
         
Other assets   296,605    246,237  
            
TOTAL ASSETS  $5,282,567   $2,511,448  
            
LIABILITIES AND STOCKHOLDERS' EQUITY           
         
Current liabilities           
         
Accounts payable and accrued expenses  $810,784   $558,338  
         
Related party payable   200,000    154,850  
         
Capital leases - current   -    149  
         
Notes payable - current, net of discount   43,723    40,897  
         
Convertible notes payable, net of discount   1,116,109    606,932  
         
Derivative liability   114,566    31,010  
         
Total current liabilities   2,285,182    1,392,176  
            
Long-term liabilities           
         
Notes payable   -    44,484  
         
Total long-term liabilities   -    44,484  
            
TOTAL LIABILITIES   2,285,182    1,436,660  
            
COMMITMENTS AND CONTINGENCY           
            
STOCKHOLDERS' EQUITY           
Preferred stock, par value $0.0005 per share; 25,000,000 shares authorized;           
         
518,750 Series A convertible preferred shares issued and outstanding as of June 30, 2015 and 593,750 shares issued and outstanding as of December 31, 2014.   258    296  
         
900 Series B convertible preferred shares issued and outstanding as of June 30, 2015 and 1,145 shares issued and outstanding as of December 31, 2014.   1    1  
         
770,000 Series C convertible preferred shares issued and outstanding as of June 30, 2015 and 0 shares issued and outstanding as of December 31, 2014.   385    -  
         
1,050,000 Series D convertible preferred shares issued and outstanding as of June 30, 2015 and 0 shares issued and outstanding as of December 31, 2014.   525    -  
         
531,666 Series E convertible preferred shares issued and outstanding as of June 30, 2015 and 0 shares issued and outstanding as of December 31, 2014.   266    -  
         
Common stock, par value $0.0004 per share; 100,000,000 shares authorized;           
         
31,224,000 shares of voting common stock issued and outstanding as of June 30, 2015 and 28,438,631 shares issued and outstanding as of December 31, 2014   12,492    11,377  
         
Stock subscription receivable   (1,231,666 )  -  
         
Additional Paid-in Capital   24,854,869    19,104,322  
         
Accumulated deficit  (20,639,745)  (18,041,208)
            
TOTAL STOCKHOLDERS' EQUITY   2,997,385    1,074,788  
            
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY  $5,282,567   $2,511,448  
         
  
OXYSURE SYSTEMS INC. 
  
STATEMENTS OF OPERATIONS 
  
   For the three months ended
June 30,


  For the six months ended
June 30,


 
   2015

  2014

  2015

  2014

 
                  
                  
Revenues, net  $1,046,019   $678,111   $1,670,533   $1,034,340  
                 
Cost of goods sold   409,183    264,856    745,039    470,446  
                 
Gross profit   636,836    413,255    925,494    563,894  
                 
                      
Operating expenses                     
                 
Research and development  $297,456   $275,974   $510,801   $277,515  
                 
Sales and marketing   329,393    154,044    794,139    241,993  
                 
Other general and administrative   621,066    259,230    1,243,350    604,987  
                 
Total operating expenses   1,247,915    689,248    2,548,290    1,124,495  
                 
                      
Loss from operating expenses   (611,079 )  (275,993 )  (1,622,796 )  (560,600 )
                 
                      
Other income (expenses)                     
                 
Interest expense   (561,791 )  (85,980 )  (892,945 )  (193,587 )
                 
Change in value of derivative liabilities   119,933    -    122,584    -  
                 
Derivative expense   (204,272 )  -    (204,272 )  -  
                 
Other income (expense)   (1,225 )  42,465    (1,108 )  58,360  
                 
Total other income (expenses)   (647,355 )  (43,515 )  (975,741 )  (135,227 )
                 
                      
Net loss  $(1,258,434 ) $(319,508 ) $(2,598,537 ) $(695,828 )
                 
                      
Basic and diluted net loss per common share  $(0.04 ) $(0.01 ) $(0.09 ) $(0.03 )
                 
                      
Weighted average common shares outstanding:                     
                 
Basic and diluted   30,215,788    25,996,642    29,587,327    25,956,948  
                 
  
OXYSURE SYSTEMS INC. 
  
STATEMENTS OF CASH FLOWS 
  
(Unaudited) 
  
   For the six months ended  
   June 30,  
    
   2015   2014  
          
CASH FLOWS FROM OPERATING ACTIVITIES:         
       
Net loss  $(2,598,537 ) $(695,828 )
         
Adjustments to reconcile net loss to net cash from operating activities:           
         
Depreciation and amortization expense   21,934    24,853  
         
Amortization of debt discount and beneficial conversion features   803,870    121,140  
         
Gain on forgiveness of debt   (37,714 )  -  
         
Gain on extinguishment of debt   -    (42,525 )
         
Excess derivative over proceeds   204,272    -  
         
Derivative liability fair value adjustment   (122,584 )  -  
         
Expenses paid on behalf of related parties   137,150    -  
         
Expenses paid by related parties   -    4,374  
         
Warrants issued for services   8,883    -  
         
Stock based compensation   106,911    17,588  
         
Common stock issued for services   62,670    -  
         
Changes in operating assets and liabilities:           
         
Accounts receivable   (341,573 )  (363,543 )
         
Inventories   (145,205 )  1,804  
         
License fees receivable   15,000    36,692  
         
Prepaid expenses and other current assets   (38,159 )  62,509  
         
Other assets   (50,368 )  -  
         
Accounts payable and accrued liabilities   282,345    304,405  
         
Deferred revenue   -    (2,976 )
         
            
NET CASH USED IN OPERATING ACTIVITIES   (1,691,105 )  (531,507 )
         
            
CASH FLOWS FROM INVESTING ACTIVITIES           
         
Purchase of property and equipment   (3,900 )  (70,651 )
         
Purchase of intangible assets   -    (198 )
         
            
NET CASH USED IN INVESTING ACTIVITIES   (3,900 )  (70,849 )
         
            
CASH FLOWS FROM FINANCING ACTIVITIES           
         
Common stock subscribed and issued for cash   80,001    10,672  
         
Preferred stock issued for cash and warrants   2,650,001    -  
         
Cash received from related parties   -    9,800  
         
Payments made to related parties   (92,000 )  (108,300 )
         
Cash received from convertible notes payable   1,461,000    247,500  
         
Payments made on convertible notes payable   (175,000 )  (192,000 )
         
Payments on capital leases   (149 )  (1,008 )
         
            
NET CASH PRODUCED BY FINANCING ACTIVITIES   3,923,853    (33,336 )
         
            
Net change in cash and cash equivalents   2,228,848    (635,692 )
         
            
Cash and cash equivalents, at beginning of period   647,093    657,673  
         
            
Cash and cash equivalents, at end of period  $2,875,941   $21,981  
         
            
Supplemental disclosure of cash flow information:           
         
Cash paid during the period for:           
         
Interest  $-   $-  
         
Income taxes  $-   $-  
         
            
Supplemental non-cash investing and financing activities:           
         
Conversion of preferred stock to common  $246   $-  
         
Conversion of convertible notes payable   804,138    -  
         
Beneficial conversion feature   808,532    -  
         
Initial value of the derivative   165,200    -  
         

The following files are available for download:

Contact Information